Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Editorial

Treatment of Lysosomal Storage Disorders (LSDs)

Author(s): ">Antonino Tuttolomondo

Volume 26 , Issue 40 , 2020

Page: [5087 - 5088] Pages: 2

DOI: 10.2174/138161282640201111114453

[1]
Platt FM, d’Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers 2018; 4(1): 27.
[2]
Sun A. Lysosomal storage disease overview. Ann Transl Med 2018; 6(24): 476.
[http://dx.doi.org/10.21037/atm.2018.11.39]
[3]
Cohen IJ, Baris HN, Mistry PK, Sands MS. Treatment for Lsds: real options for several diseases. Forward. Pediatr Endocrinol Rev 2014; 12(Suppl. 1): 71.
[4]
Wong VW, Petta S, Hiriart JB, et al. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. J Hepatol 2017; 67(3): 577-84.
[5]
Petta S, Adinolfi LE, Fracanzani AL, et al. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. J Hepatol 2018; 69(1): 18-24.
[6]
Petta S, Valenti L, Tuttolomondo A, et al. Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease. Hepatology 2017; 66(6): 1885-93.
[7]
Simonetta I, Tuttolomondo A, Daidone M, Miceli S, Pinto A. Treatment of Anderson-Fabry disease Current Pharmaceutical Design 2020 Online ahead of print 2020.
[8]
Biegstraaten M, Arngrímsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis 2015; 10: 36.
[9]
Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis 2013; 8: 47.
[http://dx.doi.org/10.1186/1750-1172-8-47]
[10]
Weidemann F, Niemann M, Störk S, et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 2013; 274(4): 331-41.
[11]
Kubaski F, Vairo F, Baldo G, Poswar FO, Corte AD, Giugliani R. Therapeutic options for mucopolysaccharidosis II (Hunter Disease). Current Pharmaceutical Design 2020. Online ahead of print. 2020.
[12]
Sheth J, Nair A. Treatment for lysosomal storage disorders Current Pharmaceutical Design 2020 Online ahead of print 2020.
[13]
Tuttolomondo A, Maida C, Pinto A. Diabetic foot syndrome: Immune-inflammatory features as possible cardiovascular markers in diabetes. World J Orthop 2015; 6(1): 62-76.
[14]
Pinto A, Tuttolomondo A, Di Raimondo D, Fernandez P, Licata G. Risk factors profile and clinical outcome of ischemic stroke patients admitted in a Department of Internal Medicine and classified by TOAST classification. Int Angiol 2006; 25(3): 261-7.
[15]
Tuttolomondo A, Di Raimondo D, Pecoraro R, et al. HLA and killer cell immunoglobulin-like receptor (KIRs) genotyping in patients with acute ischemic stroke. J Neuroinflammation 2019; 16(1): 88.

© 2022 Bentham Science Publishers | Privacy Policy